Skip to main content
JOHNSON & JOHNSON logo

JOHNSON & JOHNSON — Investor Relations & Filings

Ticker · JNJ ISIN · US4781601046 LEI · 549300G0CFPGEF6X2043 US Manufacturing
Open in API
Filings indexed 3,105 across all filing types
Latest filing 2017-12-14 Director's Dealing
Country US United States of America
Listing US JNJ

About JOHNSON & JOHNSON

https://www.jnj.com/

Johnson & Johnson is a healthcare company that operates through two primary segments: Innovative Medicine and MedTech. The Innovative Medicine division is focused on the research, development, and delivery of new treatments for complex diseases in areas such as oncology, immunology, neuroscience, and cardiopulmonary conditions. The MedTech segment develops and provides a broad portfolio of medical technologies and solutions. It innovates in fields including surgery, orthopaedics, vision, and interventional solutions, aiming to create smarter, less invasive, and more personalized healthcare treatments. The company's mission is to address significant health challenges through science-based innovation at the intersection of biology and technology.

Recent filings

Filing Released Lang Actions
Director's Dealing 2017
Director's Dealing
2017-12-14 English
Director's Dealing 2017
Director's Dealing
2017-12-14 English
PRIMARY DOCUMENT
Director's Dealing
2017-11-22 English
SC 13G/A FOR ACHILLION PHARMACEUTICALS, INC. BY JOHNSON & JOHNSON
Major Shareholding Notification
2017-11-22 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes the entry into a material definitive agreement (a Second Supplemental Indenture amending redemption provisions) and details about a new debt issuance (notes with various maturities and interest rates). The document is not a full financial report but an announcement of financing activities and agreements. The length is 4428 characters, which is relatively short and typical for an 8-K filing announcing capital market transactions. The key indicators are the description of the underwriting agreement and issuance of notes, which fits the category of Capital/Financing Update. Therefore, the appropriate classification is CAP (Capital/Financing Update).
2017-11-13 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act of 1933. It details the offering of various senior unsecured notes with specific terms, interest rates, maturity dates, underwriting discounts, and proceeds. The document includes a calculation of registration fees and detailed descriptions of the securities being registered and offered. This type of document is related to capital raising activities and financing updates rather than financial performance reports, management changes, or regulatory filings unrelated to financing. It is not an annual or quarterly report, earnings release, or legal proceeding update. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed financial terms of the offering, not just an announcement or a brief summary, supporting a high confidence level.
2017-11-09 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.